LXRX · Lexicon Pharmaceuticals, Inc. · Documents

Mar 2

Earnings call

Q4 2022 earnings call

Mar 2

Current report 8-K

Financial results

Jan 4

Current report 8-K Events of Dec 30

New debt or off-balance-sheet obligation, Unregistered sale of equity

Nov 9

Earnings call

Q3 2022 earnings call

Nov 9

Current report 8-K

Financial results

Nov 9

Quarterly report 10-Q FY2022 Q3, ended Sep 30

Quarterly report for FY2022 Q3

Net loss $23.39M

Sep 2

Current report 8-K Events of Aug 29

Entered into a material agreement

Aug 3

Quarterly report 10-Q FY2022 Q2, ended Jun 30

Quarterly report for FY2022 Q2

Net loss $24.59M

Aug 2

Earnings call

Q2 2022 earnings call

Aug 2

Current report 8-K

Financial results

Jul 29

Current report 8-K Events of Jul 27

Entered into a material agreement, Unregistered sale of equity, Regulation FD disclosure, Other events

Jun 30

Current report 8-K Events of Jun 29

Other events

May 25

Current report 8-K Events of May 20

Change to shareholders' rights, Charter or bylaw amendment, or fiscal year change, Shareholder vote results

May 5

Earnings call

Q1 2022 earnings call

May 5

Current report 8-K

Financial results

May 5

Quarterly report 10-Q FY2022 Q1, ended Mar 31

Quarterly report for FY2022 Q1

Net loss $23.48M

Apr 8

Proxy statement DEF 14A

Proxy statement

Apr 8

Proxy statement DEFA14A

Proxy statement

Mar 17

Current report 8-K

Entered into a material agreement, New debt or off-balance-sheet obligation, Unregistered sale of equity, Regulation FD disclosure

Mar 11

Proxy statement PRE 14A

Proxy statement

Mar 10

Annual report 10-K FY2021, ended Dec 31

Annual report for FY2021

Revenue $298K ▼ 98.8% Net loss $87.76M Diluted EPS -$0.60

Feb 28

Earnings call

Q4 2021 earnings call

Feb 28

Current report 8-K

Financial results

Nov 9

Quarterly report 10-Q FY2021 Q3, ended Sep 30

Quarterly report for FY2021 Q3

Revenue $23K ▼ 99.7% Net loss $23.12M Diluted EPS -$0.16

Nov 3

Earnings call

Q3 2021 earnings call

Nov 3

Current report 8-K

Financial results

Sep 9

Current report 8-K Events of Sep 3

Director or officer change, or executive pay

Aug 6

Quarterly report 10-Q FY2021 Q2, ended Jun 30

Quarterly report for FY2021 Q2

Revenue $234K ▼ 97.4% Net loss $18.07M

Aug 6

Registration statement S-3

Registration statement

Aug 2

Current report 8-K Events of Jul 30

Financial results

Aug 2

Current report 8-K Events of Jul 28

Director or officer change, or executive pay, Other events

Jul 30

Current report 8-K

Director or officer change, or executive pay, Other events

Jul 30

Earnings call

Q2 2021 earnings call

Jul 30

Current report 8-K

Financial results

May 6

Earnings call

Q1 2021 earnings call

May 6

Current report 8-K

Financial results

May 6

Quarterly report 10-Q FY2021 Q1, ended Mar 31

Quarterly report for FY2021 Q1

Revenue $27K ▼ 99.7% Net loss $20.96M

May 3

Current report 8-K Events of Apr 29

Entered into a material agreement, Change to shareholders' rights, Charter or bylaw amendment, or fiscal year change, Shareholder vote results

Apr 1

Current report 8-K Events of Mar 29

Director or officer change, or executive pay

Mar 19

Proxy statement DEF 14A

Proxy statement

Mar 19

Proxy statement DEFA14A

Proxy statement

Mar 12

Annual report 10-K FY2020, ended Dec 31

Annual report for FY2020

Revenue $24M ▼ 92.5% Net loss $58.57M Diluted EPS -$0.53

Mar 10

Earnings call

Q4 2020 earnings call

Mar 10

Current report 8-K

Financial results

Feb 19

Proxy statement PRE 14A

Proxy statement

Feb 12

Current report 8-K Events of Feb 8

Entered into a material agreement

Jan 14

Current report 8-K

Other events

Dec 18

Current report 8-K Events of Dec 16

Entered into a material agreement

Dec 11

Current report 8-K

Other events

Dec 11

Current report 8-K

Entered into a material agreement, Other events